Published Guideline
READ GUIDELINE
"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer" published on August 13, 2021 in Journal for ImmunoTherapy of Cancer (JITC) and has since been updated.
Updated Content (last reviewed 3/15/24)
SITC continually evaluates the field for practice-changing data and new FDA approvals that may affect the guideline. The information on this page provides a detailed overview of updates to the guideline content. Updates to the guideline outlined below were made with the approval of SITC's Breast Cancer CPG Expert Panel. More information on SITC Guidelines can be found here.
v1.2 Update Summary
The FDA granted accelerated approval for dostarlimab for the treatment of dMMR recurrent or advanced solid tumors (along with the VENTANA MMR RxDx Panel companion diagnostic to detect dMMR) that have progressed on or following prior treatment and who have no satisfactory alternative treatment options on August 17, 2021. Based on these approvals, the Breast Cancer CPG has been updated in the following locations: "Immunotherapy with PD-(L)1 Inhibitors for the Treatment of Advanced/Metastatic Breast Cancer" and "Diagnostics and Biomarker Testing in Patients with Advanced/Metastatic Breast Cancer." Additionally, Table 2 was updated from the original publication to include the GARNET trial data that led to the tissue-agnostic dostarlimab approval.
The FoundationOne CDx assay was approved as the companion diagnostic for identifying patients with MSI-H tumors for treatment with pembrolizumab in February 2022. Based on this approval, the Breast Cancer CPG has been updated in the following location: "Diagnostics and Biomarker Testing in Patients with Advanced/Metastatic Breast Cancer."
v1.1(A) Update Summary
On August 27, 2021, the indication for atezolizumab in combination with nab-paclitaxel as treatment for patients with triple-negative breast cancer (TNBC) whose tumors express PD-L1 was voluntarily withdrawn by the manufacturer. According to the press release announcing the withdrawal, the decision was not related to any changes in either the efficacy or safety associated with atezolizumab but rather to recent changes in the treatment landscape for TNBC. In light of this withdrawal, updates were made to narrative text and recommendations within the Breast Cancer CPG.